• SEC Filings

Aimmune Therapeutics, Inc. Exhibit
EX-99.1 2 aimt-ex991_6.htm EX-99.1 aimt-ex991_6.htm Exhibit 99.1   Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy   — Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients —   — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment —   — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time —   BRISBANE,…
To view the full exhibit click here

About AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT)

Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.